14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
HQY vs VEEV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Veeva Systems Inc. (VEEV) is the stronger overall head-to-head candidate over HealthEquity, Inc (HQY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HQY carries a Unified Composite Score of 41.2/100 (SELL) at $101.86 (23.0x Forward P/E, 26.1% operating margin), whereas VEEV carries 48.5/100 (HOLD) at $290.25 (34.8x Forward P/E, 29.9% operating margin).
Competes within the Health Information Services value chain with $48.8B market capitalization and 29.9% operating margin.
OpEx & R&D Reinvestment45.1% of Rev ($1.56B)
90D Engineering Disclosures0 Published
Investor FAQ HQY vs VEEV Key Questions & Quantitative Answers
As of Nov 17, 2026, Veeva Systems Inc. (VEEV) is the stronger overall head-to-head candidate over HealthEquity, Inc (HQY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HQY carries a Unified Composite Score of 41.2/100 (SELL) at $101.86 (23.0x Forward P/E, 26.1% operating margin), whereas VEEV carries 48.5/100 (HOLD) at $290.25 (34.8x Forward P/E, 29.9% operating margin). Technically, HQY sits in a Markup phase (RSI 53.7, CONSOLIDATION options structure) and VEEV sits in a Neutral phase (RSI 40.9, CONSOLIDATION options structure).
VEEV leads the Growth & Scale pillar: HQY posts +7.6% YoY revenue growth and +14.7% YoY earnings growth on $1.36B TTM revenue (71.2% gross margin, 26.1% operating margin), compared with VEEV at +17.6% YoY revenue growth and +39.5% YoY earnings growth on $3.46B TTM revenue (75.0% gross margin, 29.9% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), HQY cumulative revenue shifted +351.7% while VEEV shifted +272.1%. In operating R&D and SG&A reinvestment, HQY deploys 45.1% of Rev ($614M) (0 90-day corporate R&D disclosures) versus 45.1% of Rev ($1.56B) (0 disclosures) for VEEV.
HQY screens cheaper on headline valuation multiples. HQY trades at 23.0x Forward P/E, 37.4x Trailing P/E, 1.27x PEG, and 6.8x EV/Revenue (32.1% FCF margin), whereas VEEV trades at 34.8x Forward P/E, 49.4x Trailing P/E, 1.16x PEG, and 13.6x EV/Revenue (48.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HQY (11.4% ROE) versus VEEV (14.4% ROE) capital efficiency.
In options market volatility and institutional positioning, HQY carries 35.8% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 38% Vol realized risk). By comparison, VEEV carries 45.0% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.39β · 20% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.